Canasa en es it fr

Canasa Brand names, Canasa Analogs

Canasa Brand Names Mixture

  • No information avaliable

Canasa Chemical_Formula


Canasa RX_link

No information avaliable

Canasa fda sheet

Canasa FDA

Canasa msds (material safety sheet)

Canasa Synthesis Reference

No information avaliable

Canasa Molecular Weight

145.156 g/mol

Canasa Melting Point

No information avaliable

Canasa H2O Solubility

Freely soluble

Canasa State


Canasa LogP


Canasa Dosage Forms

Cream for topical administration (160 mg/g of methyl aminolevulinate equivalent to 16.0% of methyl aminolevulinate)

Canasa Indication

For topical use, in combination with 570 to 670 nm wavelength red light illumination, in the treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation (debridement using a sharp dermal curette).

Canasa Pharmacology

After topical application of methyl aminolevulinate, porphyrins will accumulate intracellularly in the treated skin lesions. The intracellular porphyrins (including PpIX) are photoactive, fluorescing compounds and, upon light activation in the presence of oxygen, singlet oxygen is formed which causes damage to cellular compartments, in particular the mitochondria. Light activation of accumulated porphyrins leads to a photochemical reaction and thereby phototoxicity to the light-exposed target cells.

Canasa Absorption

In vitro, after 24 hours the mean cumulative absorption through human skin was 0.26% of the administered dose.

Canasa side effects and Toxicity

The severity of local phototoxic reactions such as erythema, pain and burning sensation may increase in case of prolonged application time or very high light intensity.

Canasa Patient Information

Canasa Organisms Affected

Humans and other mammals